Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Prostate Cancer: Update Bulletin [June 2014]

Product Code:
596200307
Release Date:
June 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Prostate Cancer: PREVAIL trial data position Xtandi for approval in pre-chemo setting

Highlights from this event update bulletin

  • PREVAIL trial data position Xtandi for approval in pre-chemo setting
  • Efficacy of Xtandi considered similar to Zytiga
  • Ease of use, particularly the lack of prednisone, will give Xtandi a key advantage
  • Competition between Xtandi and Zytiga will be fierce in the pre-chemo setting
  • Economic pressure will intensify following the patent expiry of Zytiga and may shift use away from Xtandi
  • Xtandi’s indication may extend to the non-metastatic CRPC setting

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

 

 

 




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved